GO:2001032 regulation of double-strand break repair via nonhomologous end joining: DNA Repair Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001032 describes any process that modulates the frequency, rate or extent of double-strand break repair via nonhomologous end joining (NHEJ).
• NHEJ is a major DNA double-strand break repair pathway that directly ligates broken DNA ends without a homologous template, and its regulation is critical for genome stability.
• End resection is a key decision point that commits breaks to homologous recombination rather than NHEJ, and its control is central to pathway choice.
• Post-translational modifications of core NHEJ factors, such as lactylation of XLF and crotonylation-to-SUMOylation conversion of Ku80, directly regulate NHEJ activity and therapy resistance.
• Cancer cells with homologous recombination deficiency often become dependent on NHEJ and Polθ-mediated repair, making NHEJ regulation a therapeutic target.
• CRISPR-Cas9 gene editing outcomes are strongly influenced by the balance between NHEJ and homology-directed repair, so understanding NHEJ regulation improves precise genome editing.
Description
Double-strand breaks (DSBs) are among the most cytotoxic DNA lesions, and cells repair them primarily through nonhomologous end joining (NHEJ) or homologous recombination (HR). NHEJ directly rejoins broken DNA ends and is active throughout the cell cycle, but its inappropriate or excessive activity can cause deletions, translocations, and genome instability. The Gene Ontology term GO:2001032, regulation of double-strand break repair via nonhomologous end joining, captures the diverse cellular processes that modulate the frequency, rate, or extent of NHEJ. Understanding this regulation is essential because pathway choice between NHEJ and HR determines repair fidelity and influences cancer development, chemotherapy resistance, and the outcome of CRISPR-based genome editing. Recent studies have revealed that NHEJ is controlled at multiple levels, including DNA end resection, post-translational modifications of core factors, and recruitment of accessory proteins. This article integrates authoritative GO annotation with published literature to provide a research-grade overview of GO:2001032, its molecular players, disease relevance, and experimental approaches for studying it.
regulation of double-strand break repair via nonhomologous end joining At A Glance
| GO ID | GO:2001032 |
|---|---|
| GO term | regulation of double-strand break repair via nonhomologous end joining |
| Ontology | biological_process |
| Synonym | regulation of NHEJ |
| Definition | Any process that modulates the frequency, rate or extent of double-strand break repair via nonhomologous end joining. |
| Major function | Controls the choice, efficiency, and fidelity of NHEJ-mediated DNA double-strand break repair. |
| Key regulatory nodes | DNA end resection, Ku70/Ku80 heterodimer, DNA-PKcs, XLF, XRCC4, LIG4, and accessory factors such as AATF and Polθ. |
| Disease relevance | Cancer chemoresistance, radioresistance, and genome instability syndromes. |
| Research methods | CRISPR knockout/knock-in, reporter assays, resection assays, and post-translational modification analysis. |
What Is GO:2001032?
GO:2001032 is defined as any process that modulates the frequency, rate or extent of double-strand break repair via nonhomologous end joining. In other words, it encompasses all regulatory inputs that tune the NHEJ pathway, including proteins that promote or inhibit NHEJ, post-translational modifications of NHEJ factors, and crosstalk with other DNA repair pathways.
Why Is regulation of double-strand break repair via nonhomologous end joining Important in Cell Biology?
Regulation of NHEJ is critically important because it determines how cells repair DSBs, which in turn affects genome stability, cancer therapy response, and the precision of genome editing. Dysregulated NHEJ can drive oncogenic translocations and confer resistance to DNA-damaging therapies, while its modulation can enhance CRISPR-Cas9 homology-directed repair.
• NHEJ is a primary DSB repair pathway, and its regulation influences cell survival after DNA damage.
• End resection is a key regulatory step that commits breaks to HR and is antagonized by NHEJ factors.
• Post-translational modifications such as XLF lactylation and Ku80 SUMOylation directly regulate NHEJ efficiency and therapy resistance.
• HR-deficient tumors often rely on NHEJ and Polθ-mediated repair, making NHEJ regulation a synthetic lethal target.
• AATF-mediated enhancement of NHEJ contributes to therapeutic resistance in glioblastoma.
• CRISPR-Cas9 editing outcomes depend on the balance between NHEJ and HDR, so regulating NHEJ can improve precise editing.
• NHEJ regulation is implicated in cancer radioresistance and chemoresistance.
• Understanding NHEJ regulation aids in interpreting disease-associated mutations in DNA repair genes.
What Happens During regulation of double-strand break repair via nonhomologous end joining?
DNA End Resection and Pathway Choice
In simple terms: Cells first decide whether to trim the broken DNA ends, which determines if they will use NHEJ or HR.
The initiation of DNA end resection is a critical regulatory step that dictates repair pathway choice. Resection generates single-stranded DNA and promotes homologous recombination, thereby antagonizing NHEJ. Regulatory factors that limit resection, such as 53BP1 and its effectors, favor NHEJ, while resection-promoting factors favor HR. Recent reviews highlight that resection is tightly controlled by cell cycle, chromatin context, and post-translational modifications.
Recognition and Synapsis of DNA Ends
In simple terms: The Ku protein ring grabs the broken ends and brings them together for joining.
The Ku70/Ku80 heterodimer rapidly binds DNA ends and recruits DNA-PKcs, forming the DNA-PK holoenzyme that aligns broken ends. This step is regulated by modifications of Ku proteins; for example, conversion of Ku80 K568 crotonylation to SUMOylation facilitates NHEJ and promotes cancer radioresistance. The stability and activity of the Ku complex are thus key regulatory nodes in NHEJ.
Ligation and Accessory Factor Regulation
In simple terms: After the ends are held together, a ligase complex seals the break, and accessory proteins fine-tune this step.
The XRCC4-XLF-LIG4 complex performs the final ligation step of NHEJ. Regulation of XLF by lactylation promotes NHEJ and chemoresistance in cancer, demonstrating that post-translational modifications directly control ligation efficiency. Additional factors such as AATF can enhance NHEJ and contribute to therapeutic resistance in glioblastoma. These examples illustrate that NHEJ is not a static process but is dynamically regulated at the ligation stage.
Crosstalk with Alternative End Joining
In simple terms: When classic NHEJ is compromised, cells can use backup repair that often involves polymerase theta.
Polymerase theta (Polθ) mediates alternative end joining, which is upregulated in HR-deficient tumors and represents a vulnerability. The regulation of NHEJ and alternative end joining is interconnected, as loss of core NHEJ factors can shift repair toward Polθ-mediated mechanisms. This crosstalk is important for understanding therapy resistance and for designing combination treatments.
Key Genes Involved in GO:2001032 regulation of double-strand break repair via nonhomologous end joining
The following genes and proteins are central to the regulation of NHEJ and are frequently studied in the context of GO:2001032.
| Gene | Major Role | Research Relevance |
|---|---|---|
| XRCC6 (Ku70) | Binds DNA ends as heterodimer with Ku80 | Core NHEJ factor; knockout impairs NHEJ |
| XRCC5 (Ku80) | Forms Ku heterodimer; recruits DNA-PKcs | Post-translational modifications regulate NHEJ and radioresistance |
| PRKDC (DNA-PKcs) | Catalytic subunit of DNA-PK; activates NHEJ | Key kinase in NHEJ; target for inhibitor studies |
| LIG4 | DNA ligase IV; seals breaks | Essential for ligation; mutations cause immunodeficiency |
| XRCC4 | Stabilizes LIG4 and stimulates ligation | Core ligation complex component |
| NHEJ1 (XLF) | Stimulates ligation and end alignment | Lactylation regulates NHEJ and chemoresistance |
| AATF | Enhances NHEJ and DNA damage repair | Overexpression linked to glioblastoma resistance |
| POLQ (Polθ) | Mediates alternative end joining | Synthetic lethal target in HR-deficient cancers |
| TP53BP1 | Promotes NHEJ by limiting resection | Key regulator of pathway choice |
| BRCA1 | Promotes HR and antagonizes NHEJ | Loss shifts repair toward NHEJ |
| ATM | Signals DNA damage and influences repair choice | Regulates resection and NHEJ |
| MRE11 | Initiates end resection | Resection regulation affects NHEJ |
| RAD50 | Part of MRN complex with MRE11 | Involved in resection and signaling |
| NBN (Nibrin) | Part of MRN complex | Mutations cause Nijmegen breakage syndrome |
| EXO1 | Long-range resection nuclease | Resection antagonizes NHEJ |
| BLM | Helicase involved in resection | Regulates repair pathway choice |
| CTIP (RBBP8) | Promotes end resection | Antagonizes NHEJ |
| 53BP1 | See TP53BP1 | Regulates NHEJ vs HR choice |
How Is regulation of double-strand break repair via nonhomologous end joining Regulated?
Regulation of NHEJ occurs at multiple levels, including cell cycle-dependent control of end resection, post-translational modifications of core factors, and crosstalk with other repair pathways. For example, lactylation of XLF and SUMOylation of Ku80 directly modulate NHEJ activity and influence chemoresistance and radioresistance. Additionally, AATF enhances NHEJ in glioblastoma, contributing to therapeutic resistance. These regulatory mechanisms are potential targets for sensitizing cancer cells to DNA-damaging therapies.
regulation of double-strand break repair via nonhomologous end joining and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NHEJ1 (XLF) | Chemoresistance in cancer | Knockout and lactylation-site point mutant cell lines |
| XRCC5 (Ku80) | Radioresistance | Knock-in of SUMOylation-mimetic or -deficient mutants |
| AATF | Glioblastoma therapeutic resistance | Overexpression and knockout in glioblastoma cells |
| POLQ | HR-deficient cancer synthetic lethality | Knockout in BRCA-mutant backgrounds |
| LIG4 | Immunodeficiency and radiosensitivity | Patient-derived cells and knockout models |
Cancer Chemoresistance and Radioresistance
Upregulation or enhanced activity of NHEJ factors can promote resistance to chemotherapy and radiotherapy. Lactylation of XLF increases NHEJ and chemoresistance in cancer, while Ku80 SUMOylation facilitates NHEJ and radioresistance. AATF-mediated enhancement of NHEJ also drives therapeutic resistance in glioblastoma. Targeting these regulatory modifications may overcome resistance.
Homologous Recombination Deficiency and Synthetic Lethality
Tumors with HR deficiency, such as BRCA1/2-mutant cancers, become dependent on NHEJ and Polθ-mediated alternative end joining. This dependency creates a synthetic lethal opportunity, and inhibitors of Polθ or NHEJ factors are being explored as therapeutic strategies.
Genome Instability Syndromes
Defects in NHEJ core factors such as LIG4, XRCC4, and XLF cause immunodeficiency and radiosensitivity syndromes, highlighting the importance of proper NHEJ regulation for human health. Dysregulated resection also contributes to genome instability.
From regulation of double-strand break repair via nonhomologous end joining-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene affect NHEJ efficiency? | CRISPR knockout cell lines and NHEJ reporter assays |
| Does a specific post-translational modification regulate NHEJ? | Point-mutation knock-in of modification sites (e.g., XLF lactylation, Ku80 SUMOylation) |
| Does overexpression of a factor drive therapy resistance? | Overexpression cell models and drug sensitivity assays |
| How does a mutation affect pathway choice? | Knock-in of patient-derived mutations and resection assays |
| Can NHEJ modulation improve HDR efficiency? | CRISPR-Cas9 editing with NHEJ inhibitors or knockouts |
| What is the role of Polθ in HR-deficient cells? | POLQ knockout in BRCA-mutant cancer models |
How to Study the regulation of double-strand break repair via nonhomologous end joining Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EJ5-GFP reporter | NHEJ frequency | Quantify NHEJ after gene knockout |
| BrdU staining | DNA end resection | Assess pathway choice |
| Mass spectrometry | Post-translational modifications | Identify lactylation/SUMOylation sites |
| Immunoprecipitation | Protein interactions | Study Ku70/Ku80 complex formation |
| CRISPR-Cas9 HDR assay | HDR efficiency | Optimize precise editing |
| Drug sensitivity assays | Chemoresistance | Test NHEJ inhibitors |
| Comet assay | DNA damage and repair | Measure DSB repair kinetics |
| Live-cell imaging | Recruitment of NHEJ factors | Visualize repair foci |
Reporter Assays for NHEJ Activity
NHEJ reporter assays, such as the EJ5-GFP system, measure the frequency of end joining after induction of double-strand breaks. These assays are widely used to quantify changes in NHEJ efficiency upon gene knockout or overexpression.
DNA End Resection Assays
Resection can be measured by native BrdU staining or quantitative PCR-based assays that detect single-stranded DNA at breaks. These methods help determine whether a regulatory factor shifts repair toward HR or NHEJ.
Post-Translational Modification Analysis
Mass spectrometry, immunoprecipitation, and modification-specific antibodies are used to detect lactylation, SUMOylation, and other modifications on NHEJ factors. Such analyses reveal how modifications regulate NHEJ activity.
CRISPR-Cas9 Editing and HDR Enhancement
CRISPR-Cas9 editing combined with NHEJ inhibition or knockout of NHEJ factors can increase homology-directed repair efficiency. This approach is valuable for generating precise knock-in models.
How CRISPR Can Be Used to Study GO:2001032 regulation of double-strand break repair via nonhomologous end joining
Knockout
CRISPR knockout of NHEJ genes such as XRCC6, XRCC5, LIG4, or NHEJ1 allows researchers to assess their requirement for NHEJ and their impact on therapy response. Knockout of POLQ in HR-deficient cells can reveal synthetic lethality.
Point Mutation
Point mutations at post-translational modification sites, such as XLF lactylation sites or Ku80 K568, can be introduced to test whether specific modifications regulate NHEJ and resistance. These models provide mechanistic insights beyond simple knockout.
Knock-in
Knock-in of patient-derived mutations or modification-mimetic variants can model disease-associated NHEJ dysregulation. For example, knock-in of SUMOylation-mimetic Ku80 can mimic radioresistance.
Overexpression
Overexpression of NHEJ factors such as AATF or XLF can drive therapeutic resistance and is used to study gain-of-function mechanisms. Overexpression models complement knockout studies to establish causality.
How EDITGENE Supports regulation of double-strand break repair via nonhomologous end joining Research
Researchers studying regulation of double-strand break repair via nonhomologous end joining-related genes often need to determine whether a candidate gene is causally involved in NHEJ regulation, therapy resistance, or genome stability. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for regulation of double-strand break repair via nonhomologous end joining research.
Frequently Asked Questions About regulation of double-strand break repair via nonhomologous end joining
What is GO:2001032?
GO:2001032 is the Gene Ontology term for regulation of double-strand break repair via nonhomologous end joining, describing any process that modulates the frequency, rate or extent of NHEJ.
What genes are involved in regulation of double-strand break repair via nonhomologous end joining?
Key genes include XRCC6 (Ku70), XRCC5 (Ku80), PRKDC (DNA-PKcs), LIG4, XRCC4, NHEJ1 (XLF), AATF, and POLQ, among others.
How is NHEJ regulated?
NHEJ is regulated by DNA end resection, post-translational modifications of core factors, and crosstalk with homologous recombination.
What is the role of XLF in NHEJ?
XLF stimulates ligation and end alignment, and its lactylation promotes NHEJ and chemoresistance in cancer.
How does Ku80 modification affect NHEJ?
Conversion of Ku80 K568 crotonylation to SUMOylation facilitates NHEJ and promotes cancer radioresistance.
Why is NHEJ important in cancer?
Enhanced NHEJ can drive chemoresistance and radioresistance, while HR-deficient tumors depend on NHEJ and Polθ-mediated repair.
How can I study NHEJ regulation in the lab?
Common methods include NHEJ reporter assays, resection assays, post-translational modification analysis, and CRISPR knockout or knock-in models.
What is the relationship between NHEJ and CRISPR editing?
CRISPR-Cas9 editing outcomes depend on the balance between NHEJ and homology-directed repair, and inhibiting NHEJ can improve HDR efficiency.
What diseases are linked to NHEJ dysregulation?
Cancer chemoresistance, radioresistance, and genome instability syndromes such as LIG4 deficiency are linked to NHEJ dysregulation.
How does AATF regulate NHEJ?
AATF enhances NHEJ and DNA damage repair, contributing to therapeutic resistance in glioblastoma.
Conclusion
GO:2001032 encompasses the diverse regulatory mechanisms that control NHEJ, a critical DNA double-strand break repair pathway. From end resection to post-translational modifications of core factors, NHEJ regulation influences genome stability, cancer therapy response, and genome editing outcomes. Continued research into these regulatory nodes will inform new therapeutic strategies and improve precise genome engineering.
References
- 1. Symington LS et al.. 2011. Double-strand break end resection and repair pathway choice.. Annu Rev Genet 45:247-71 PMID: 21910633
- 2. Cejka P et al.. 2021. DNA End Resection: Mechanism and Control.. Annu Rev Genet 55:285-307 PMID: 34813349
- 3. Jin M et al.. 2025. Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer.. Mol Cell 85(14):2654-2672.e7 PMID: 40680721
- 4. Ceccaldi R et al.. 2015. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.. Nature 518(7538):258-62 PMID: 25642963
- 5. Ceccaldi R et al.. 2025. Mechanisms and regulation of DNA end resection in the maintenance of genome stability.. Nat Rev Mol Cell Biol 26(8):586-599 PMID: 40133633
- 6. Zhao H et al.. 2025. Conversion of Ku80 K568 crotonylation to SUMOylation facilitates DNA non-homologous end joining and cancer radioresistance.. Signal Transduct Target Ther 10(1):127 PMID: 40254688
- 7. Chu VT et al.. 2015. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.. Nat Biotechnol 33(5):543-8 PMID: 25803306
- 8. Mi L et al.. 2025. Elevated nonhomologous end-joining by AATF enables efficient DNA damage repair and therapeutic resistance in glioblastoma.. Nat Commun 16(1):4941 PMID: 40436899
